Want to see JP:4925 full AI Analyst Report?

HABA Laboratories, Inc. (4925) Price & Analysis

1 Followers

4925 Stock Chart & Stats

¥1660.00

-¥21.00(-1.26%)

At close: Jan 08 4:00 PM EST

¥1660.00

-¥21.00(-1.26%)

Day’s Range― - ―

52-Week Range¥1,609.00 - ¥1,849.00

Previous CloseN/A

Volume6.60K

Average Volume (3M)2.14K

Market Cap

¥6.46B

Enterprise Value¥1.85B

Total Cash (Recent Filing)¥4.48B

Total Debt (Recent Filing)¥1.56B

Price to Earnings (P/E)8.5

Beta0.25

Next Earnings

Aug 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield2.38%

Share Statistics

EPS (TTM)169.00

Shares Outstanding3,935,000

10 Day Avg. Volume2,940

30 Day Avg. Volume2,136

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)0.67

Price to Sales (P/S)0.53

P/FCF Ratio5.54

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

High Gross MarginsSustained gross margins near 65–71% indicate durable product-level economics and pricing power in skincare. High gross margins provide long-term room to absorb cost inflation, support marketing and R&D reinvestment, and underpin profitability even if top-line growth is only modest.

Low Leverage / De-risked Balance SheetVery low debt-to-equity (~0.12) and improving leverage give financial flexibility for investment, dividend consistency, or bolt-on M&A. Conservative leverage reduces default risk in downturns and allows the firm to fund growth or weather cyclical demand without stressing cash flows.

Brand Focus And Multi-channel DistributionA clear product positioning (additive-free, high-quality ingredients) combined with diversified channels (direct, retail, e-commerce, wholesale) supports resilient demand and customer loyalty. Multi-channel reach lowers single-channel dependence and aids steady revenue over time.

Bears Say

Modest Net MarginsDespite strong gross margins, net margin near 6% leaves limited buffer for margin compression from rising SG&A or raw-material costs. Modest bottom-line margins constrain internal reinvestment capacity and mean profitability is more sensitive to adverse cost or demand shocks.

Revenue Stabilized, Limited GrowthFlat revenues with only small recent upticks suggest the company faces structural limits to top-line expansion. Without sustained revenue growth, earnings improvements rely mainly on margin and cost control, which may cap long-term upside and make returns dependent on operational execution.

Historic Cash-flow Volatility And Recent Recovery UnprovenPast negative and volatile cash flows, plus a recent earnings turnaround, imply execution risk: the company has not yet demonstrated sustained cash generation through a full cycle. This raises uncertainty around consistent dividend funding, capex, and debt reduction plans.

4925 FAQ

What was HABA Laboratories, Inc.’s price range in the past 12 months?

HABA Laboratories, Inc. lowest stock price was ¥1609.00 and its highest was ¥1849.00 in the past 12 months.

What is HABA Laboratories, Inc.’s market cap?

HABA Laboratories, Inc.’s market cap is ¥6.46B.

When is HABA Laboratories, Inc.’s upcoming earnings report date?

HABA Laboratories, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.

How were HABA Laboratories, Inc.’s earnings last quarter?

HABA Laboratories, Inc. released its earnings results on May 11, 2026. The company reported ¥116.83 earnings per share for the quarter, beating the consensus estimate of N/A by ¥116.83.

Is HABA Laboratories, Inc. overvalued?

According to Wall Street analysts HABA Laboratories, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does HABA Laboratories, Inc. pay dividends?

HABA Laboratories, Inc. pays a Annually dividend of ¥40 which represents an annual dividend yield of 2.38%. See more information on HABA Laboratories, Inc. dividends here

What is HABA Laboratories, Inc.’s EPS estimate?

HABA Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does HABA Laboratories, Inc. have?

HABA Laboratories, Inc. has 3,935,000 shares outstanding.

What happened to HABA Laboratories, Inc.’s price movement after its last earnings report?

HABA Laboratories, Inc. reported an EPS of ¥116.83 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.118%.

Which hedge fund is a major shareholder of HABA Laboratories, Inc.?

Currently, no hedge funds are holding shares in JP:4925

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

HABA Laboratories, Inc.

Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cleansers, toners, specialized treatments, and squalane oils, while their hair and body offerings include shampoos, conditioners, soaps, and various hair and hand care solutions. Consumers can acquire these products through multiple avenues, such as mail order, their online platform, various retail outlets including drug and variety stores, and at around 70 dedicated HABA shops located in major department stores and shopping complexes.